Countdown To The Bell: (SHPH) Surpasses Key Technical Levels On Approx. 35% Move

*Sponsored Market Crux Initiates Coverage on (SHPH)! Here’s What We Can Tell You—Right Now… (SHPH) Is Operating In One Of The Fastest-Growing Biotechnology  Corridors In The Country. (SHPH) Has A Razor-Thin Float With Fewer Than 3.5M Shares  Available To The Public.  In Just Six Sessions, (SHPH) Recently Moved Approx. 57% From $0.3501  To $0.55, Showing The Potential For Significant Swings. Projected Growth To $5.68B In The Glioblastoma Space Aligns  With (SHPH)’s Current Direction. Recent Progress In A Phase 2 Trial Positions (SHPH) In  A High-Need Area Of Oncology. Pipeline Projects At (SHPH) Include Immune-Enhancing Therapies  And Advanced Diagnostics. April 11, 2025 Dear Reader, This is why we do this. Despite what’s going on across the broader markets—we’re always on the hunt for a potential breakout. Now I need to ask you. Did you pull up (SHPH) yet? There’s about 15 minutes to go before the bell rings.  (SHPH) surpassed several key moving averages on its approximately 35% overnight move from $.40 to $.54 this morning’s early session, including its 5-Day, 20-Day, and 50-Day. After-hours headlines can move fast—and so can the companies tied to them. Shuttle Pharmaceuticals (Nasdaq: SHPH) announced a provisional patent filing after the bell for PSMA-Targeted PARP Inhibitor Conjugates, a next-gen approach to prostate cancer therapy developed in partnership with Dr. Alan Kozikowski, the chemist behind breakthrough agents like Pylarify® and Pluvicto®. With this development, (SHPH) expands its diagnostics arm—Shuttle Diagnostics—and advances PSMA-B and PC-RAD with help from UCSF.  As the global PSMA-focused market trends toward $2B, this new IP could become a major part of the conversation. Shuttle Pharmaceuticals (Nasdaq: SHPH) has been operating just outside the spotlight… until now. Based in Gaithersburg, Maryland—a region pulsing with biotech activity and surrounded by over 200 firms—(SHPH) is situated right in the heart of one of the most innovation-focused zones in the country.  And just miles from the NIH and FDA, the company sits within arm’s reach of two of the most influential institutions in medical science. It’s not just the location that caught our attention.  It’s the movement.  The float.  The pipeline. And the timing.  We’re now initiating coverage on Shuttle Pharmaceuticals (Nasdaq: SHPH)—and based on what we’re seeing, this may not stay under the radar much longer. When Supply Is This Thin, It Doesn’t Take Much to Move the Needle… One of the first things that jumps off the page? Supply—or more specifically, how little of it exists. With fewer than 3.5M shares in the public float, (SHPH) falls squarely into ultra-low float territory—where the balance between supply and demand can tip fast. And when that balance tilts, things can get sharp—quickly. This isn’t just theory—it’s already begun. From $0.3501 on March 31 to $0.55 by April 7, (SHPH) logged a move of approximately 57% in just six sessions. That kind of action—on that little float—shows just how fast momentum can build when the spotlight begins to shift. In situations like this, even a modest uptick in attention has the potential to spark a chain reaction. And if the recent move was any indication, (SHPH) may be entering a phase where scarcity meets traction—and that’s a setup worth watching closely. (SHPH) Pushes Forward in a Market Poised to Hit $5.68B… With a market cap still under $2.5M, (SHPH) remains off most radars—for now. But that may be changing fast. The company recently marked a key milestone in its Phase 2 clinical trial of Ropidoxuridine, a radiation sensitizer being studied for use in glioblastoma—one of the most aggressive and hard-to-treat forms of brain cancer. And the timing of this progress couldn’t be more aligned with the broader picture. The global glioblastoma multiforme (GBM) treatment space is entering a new phase—where traditional approaches like surgery and chemotherapy are no longer seen as sufficient on their own.  Demand is steadily shifting toward more targeted, personalized solutions that can address both survival and quality of life. As of the last update, 40% of targeted patients have already been enrolled in (SHPH)’s randomized trial phase.  Clinical sites include high-profile centers like Georgetown University Medical Center and the University of Virginia Cancer Center—adding weight to the company’s growing presence. And now, take a look at this: The global GBM treatment market is projected to exceed $3B in 2025—and may reach approximately $5.68B by 2033. That’s nearly 89% growth, driven by breakthroughs in immunotherapy, radiation sensitizers, and next-gen diagnostics. In short: this is no small category—and (SHPH) is building in the right direction, at a time when the broader sector is expanding fast. Not Just One Focus—(SHPH) Is Advancing Multiple Programs… (SHPH) isn’t built around a single program—and the pipeline tells the story.  In addition to its lead candidate, the company is developing SP-2-225, a selective HDAC6 inhibitor designed to work alongside radiation therapy by enhancing immune system responses. Early-stage research suggests it may have the potential to activate systemic immune activity, extending its impact beyond localized control. The company is also moving forward in the diagnostic space. One of its innovations, PC-RAD, is a blood-based test aimed at evaluating radiation therapy outcomes in prostate cancer.  Another, PSMA-B, is a dual-use molecule with potential applications in both imaging and treatment of metastatic disease.  Development of PSMA-B is being accelerated through a research collaboration with the University of California, San Francisco (UCSF)—a partnership that adds academic credibility and momentum to the project. (SHPH)’s work spans both therapeutic and diagnostic fronts, and the depth of its pipeline reflects a strategy built around long-term innovation, not just a single outcome.  Maryland’s Biotech Belt Just Got a Little More Interesting  With (SHPH) In The Picture… This isn’t just about one company—it’s about being in the right place, with the right people, working on real-world solutions. In March 2025, (SHPH) appointed Christopher Cooper as interim Co-CEO to help guide the next phase of its growth and expand the company’s visibility.  Cooper brings over 27 years of experience spanning both public and private firms, and his leadership arrives at a time when the company is gaining traction on multiple fronts.  Soon after his appointment, (SHPH) completed a $5.75M underwritten offering—securing additional capital to advance its pipeline and fuel near-term development efforts. It’s no coincidence that (SHPH) is based in Gaithersburg, Maryland—one of the most densely concentrated biotechnology corridors in the country.  This location offers more than just an address.  It provides access to one of the highest concentrations of STEM talent in the U.S., a thriving $17B life sciences ecosystem, and direct proximity to the NIH and FDA—two of the most influential institutions in global health and regulatory science.  For a company focused on clinical advancement and scientific innovation, it’s exactly the kind of environment that can support real progress. (SHPH) Just Hit Our Watchlist—Here’s Why It Stands Out Now… There’s a reason this company landed on our radar. Between its lean float, recent clinical progress, added leadership depth, and new capital, (SHPH) may be entering a phase where under-the-surface developments begin catching wider attention. We have officially announced coverage on (SHPH) and have it at the top of our watchlist right now—you may want to do the same. 7 Reasons Why (SHPH) Just Shot To The Top Of Radar… 1. Razor-Thin Float: With less than 3.5M shares circulating in the public float, even a modest shift in demand could lead to the potential for significant swings—especially in a setup like (SHPH)'s. 2. Market Recognition: From $0.3501 on March 31 to $0.55 by April 7, (SHPH) has already demonstrated how thin supply can translate into sharp upside when interest begins to build. 3. Growing Global Market: The glioblastoma treatment space is projected to exceed $3B in 2025—and may reach around $5.68B by 2033, aligning with (SHPH)’s ongoing work in this space. 4. Advancing a Phase 2 Trial: The company recently hit a milestone in its Phase 2 trial of Ropidoxuridine, aimed at improving radiation response in glioblastoma patients—a high-need area of oncology that (SHPH) is actively addressing. 5. Multiple Programs in Development: Beyond its lead candidate, (SHPH) is advancing a selective HDAC6 inhibitor and developing diagnostic tools like PC-RAD and PSMA-B, with academic collaboration underway at UCSF. 6. Strategic Biotech Hub Location: Based in Gaithersburg, Maryland—home to over 200 biotech firms and near the NIH and FDA—(SHPH) benefits from a location built for innovation, research access, and regulatory proximity. 7. New Leadership and Capital: In March 2025, a new interim Co-CEO with 27+ years of experience was appointed, and shortly after, (SHPH) closed a $5.75M underwritten offering to fund upcoming developments. Take A Quick Look At (SHPH)... With several key developments now stacking up—clinical momentum, a deeper pipeline, experienced leadership, and fresh funding—Shuttle Pharmaceuticals (Nasdaq: SHPH) has quickly moved into focus. Combine that with its ultra-low float, recent move on the chart, and exposure to a high-growth segment projected to reach $5.68B by 2033—and there’s no question it deserves a closer look. We’ve got our full attention on (SHPH) right now.  Please tell me you’re watching this. (SHPH) surpassed several key moving averages on its approximately 35% overnight move from $.40 to $.54 this morning’s early session, including its 5-Day, 20-Day, and 50-Day.  My next update could be coming very soon–keep an eye out for it. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 04/10/2025 and ending on 04/11/2025 to publicly disseminate information about (SHPH:US) via digital communications. Under this agreement, Headline Media LLC has been paid ten thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their member own shares of (SHPH:US). Please see important disclosure information here: https://marketcrux.com/disclosure/shph/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice